Stay updated with breaking news from Tim Clackson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024...
Theseus Pharmaceuticals has announced that the development of THE-630 as a potential therapeutic option for patients with gastrointestinal stromal tumor has been terminated, and enrollment to the ongoing phase 1/2 trial evaluating the agent’s safety and efficacy in this population has been discontinued.
-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a...
-- THE-630 demonstrates encouraging safety profile through Cohort 6 , supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both... | May 25, 2023
-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed...